Back to Search
Start Over
Sorafenib for the treatment of multiple myeloma.
- Source :
-
Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2016 Jun; Vol. 25 (6), pp. 743-9. Date of Electronic Publication: 2016 Apr 06. - Publication Year :
- 2016
-
Abstract
- Introduction: Sorafenib is an orally available compound that acts predominantly by targeting the Ras/Raf/MEK/ERK pathway and by inhibiting the vascular endothelial growth factor (VEGF). Since the Ras/Raf/MEK/ERK pathway is implicated in the proliferation of multiple myeloma (MM) cells and VEGF in bone marrow neovascularization, sorafenib is a drug offering the potential for targeting two important pathogenetic mechanisms involved in MM. Thus, sorafenib is being proposed for use in MM.<br />Areas Covered: In this review, the authors discuss the rationale for the use of sorafenib in MM. They then summarize the clinical development of sorafenib in MM, from initial Phase I to Phase II studies. A systematic literature review of the trials was performed using PubMed.<br />Expert Opinion: Preliminary data from phase I/II trials showed that sorafenib had a good safety profile but minimal anti-myeloma activity as a single agent in relapsed/refractory patients. Results of phase II trials, evaluating sorafenib combined with new drugs, such as bortezomib and lenalidomide are eagerly awaited.
- Subjects :
- Antineoplastic Agents adverse effects
Antineoplastic Agents pharmacology
Antineoplastic Combined Chemotherapy Protocols adverse effects
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bortezomib administration & dosage
Cell Proliferation drug effects
Humans
Lenalidomide
Multiple Myeloma pathology
Niacinamide adverse effects
Niacinamide pharmacology
Niacinamide therapeutic use
Phenylurea Compounds adverse effects
Phenylurea Compounds pharmacology
Protein Kinase Inhibitors adverse effects
Protein Kinase Inhibitors pharmacology
Protein Kinase Inhibitors therapeutic use
Sorafenib
Thalidomide administration & dosage
Thalidomide analogs & derivatives
Antineoplastic Agents therapeutic use
Multiple Myeloma drug therapy
Niacinamide analogs & derivatives
Phenylurea Compounds therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1744-7658
- Volume :
- 25
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Expert opinion on investigational drugs
- Publication Type :
- Academic Journal
- Accession number :
- 26998658
- Full Text :
- https://doi.org/10.1517/13543784.2016.1169272